BeiGene | Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Beigene Study ID

BGB-A317-305

ClinicalTrials.gov ID

NCT03777657

EudraCT Number

2018-000312-24

China Drug Trials ID

CTR20181841

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents